149 related articles for article (PubMed ID: 17523707)
1. Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia.
Stefanutti C; Bucci A; Di Giacomo S; Fraone N; Pace A; Mareri M; Musca A; Mammarella A
Clin Drug Investig; 2004; 24(8):465-77. PubMed ID: 17523707
[TBL] [Abstract][Full Text] [Related]
2. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
Adkins JC; Faulds D
Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.
Ellen RL; McPherson R
Am J Cardiol; 1998 Feb; 81(4A):60B-65B. PubMed ID: 9526816
[TBL] [Abstract][Full Text] [Related]
4. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
5. Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study.
Vega GL; Vajja M; Palacio N; Caterp NB; Grundy SM
Curr Ther Res Clin Exp; 2006 Sep; 67(5):321-33. PubMed ID: 24678105
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
Farnier M; Bonnefous F; Debbas N; Irvine A
Arch Intern Med; 1994 Feb; 154(4):441-9. PubMed ID: 8117177
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
Farnier M; Retterstøl K; Steinmetz A; Császár A
Diab Vasc Dis Res; 2012 Jul; 9(3):205-15. PubMed ID: 22228773
[TBL] [Abstract][Full Text] [Related]
8. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
[TBL] [Abstract][Full Text] [Related]
9. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
Keating GM; Ormrod D
Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia.
Gholami K; Tavakoli N; Maleki M; Shafiee A
J Clin Pharm Ther; 1998 Jun; 23(3):213-21. PubMed ID: 9831973
[TBL] [Abstract][Full Text] [Related]
11. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, and efficacy of simvastatin and fenofibrate--a multicenter study. Simvastatin-Fenofibrate Study Group.
Ziegler O; Drouin P
Cardiology; 1990; 77 Suppl 4():50-7. PubMed ID: 2073672
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
[TBL] [Abstract][Full Text] [Related]
15. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.
Park S; Kang HJ; Rim SJ; Ha JW; Oh BH; Chung N; Cho SY
Clin Ther; 2005 Jul; 27(7):1074-82. PubMed ID: 16154486
[TBL] [Abstract][Full Text] [Related]
16. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
17. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610
[TBL] [Abstract][Full Text] [Related]
18. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Curr Med Res Opin; 2009 Aug; 25(8):1973-83. PubMed ID: 19555253
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
20. Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
Kipnes MS; Roth EM; Rhyne JM; Setze CM; Lele A; Kelly MT; Sleep DJ; Stolzenbach JC
Clin Drug Investig; 2010; 30(1):51-61. PubMed ID: 19995098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
